Bioscience I. 2017 Ltd F2 Sells 29,631 Shares of Cullinan Oncology, Inc. (NASDAQ:CGEM) Stock

Cullinan Oncology, Inc. (NASDAQ:CGEM – Get Rating) major shareholder Bioscience I. 2017 Ltd F2 sold 29,631 shares of the business’s stock in a transaction on Thursday, June 23rd. The stock was sold at an average price of $13.00, for a total transaction of $385,203.00. Following the transaction, the insider now owns 537,392 shares of the company’s stock, valued at approximately $6,986,096. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

NASDAQ CGEM traded up $0.59 during trading hours on Thursday, hitting $13.32. The company had a trading volume of 288,158 shares, compared to its average volume of 401,262. Cullinan Oncology, Inc. has a 1-year low of $7.30 and a 1-year high of $30.33. The company has a market cap of $596.51 million, a PE ratio of -7.53 and a beta of 0.17. The business has a 50 day moving average of $11.14 and a 200-day moving average of $12.93.

Cullinan Oncology (NASDAQ:CGEM – Get Rating) last released its quarterly earnings data on Monday, May 16th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.61) by $0.34. On average, sell-side analysts predict that Cullinan Oncology, Inc. will post 3.39 earnings per share for the current year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC boosted its stake in Cullinan Oncology by 80.8% in the third quarter. Geode Capital Management LLC now owns 421,238 shares of the company’s stock valued at $9,507,000 after acquiring an additional 188,316 shares in the last quarter. Allspring Global Investments Holdings LLC acquired a new stake in shares of Cullinan Oncology during the fourth quarter worth about $166,000. ProShare Advisors LLC acquired a new stake in shares of Cullinan Oncology during the fourth quarter worth about $183,000. Nextech Invest AG acquired a new stake in shares of Cullinan Oncology during the fourth quarter worth about $18,842,000. Finally, Virtus ETF Advisers LLC boosted its stake in shares of Cullinan Oncology by 52.1% during the fourth quarter. Virtus ETF Advisers LLC now owns 10,536 shares of the company’s stock worth $163,000 after buying an additional 3,611 shares during the period. Institutional investors own 93.62% of the company’s stock.

Separately, HC Wainwright reiterated a “buy” rating and set a $50.00 target price on shares of Cullinan Oncology in a research note on Tuesday, May 17th.

About Cullinan Oncology (Get Rating)

Cullinan Oncology Inc, a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer.

See Also